Your Yourlocation: Home > Tiotropium bromide(136310-93-5) significantly delayed the onset of the first acute exacerbation in patients with COPD

The other two 6-month trial designs were similar to those described above except that the salmeterol group was administered in a dose of 50 g twice daily. The two trials consisted of 1,207 subjects, and after 6 months of treatment, the tiotropium bromide(136310-93-5) group (23 to 24 h after sustained administration) had an increase of 0.12 L from day 1, the salmeterol group, FEV1 (11 to 12 hours before dosing) were significantly higher than baseline values on Day 1, with a statistically significant difference. The Peak and mean FEV1 in the tiotropium group were 83 mL and 77 mL higher than those in the salmeterol group, respectively (P <0.01) at 3 h post-dose; the other trial did not provide a specific figure, but the difference was statistically Significant P <0.05).

Recently published in the New England Journal of Medicine, a treatment of COPD4a with tiotropium bromide(136310-93-5) test, is by far the largest clinical study of COPD. In the study, 5993 patients with a diagnosis of COPD were enrolled in the study, with FEV1 <70% And FEV1 / FVC <70%. Patients were randomized to receive tiotropium 18 μg · d-1 or placebo via a dry powder inhaler. The two groups of patients can be used in addition to other inhaled anticholinergic drugs other than the respiratory system drugs, And to quit smoking education. The primary end point was the mean annual rate of decline in FEV1 from the time the study drug was administered (at steady state) to the end of the study and before and after the use of bronchodilator. The quality of health-related quality of life assessed by the St. George Respiratory Questionnaire (SGRQ) was ≥ 4 units of clinical significance; (3) COPD acute exacerbation and associated hospitalization times; (4) all-cause mortality. Studies have shown that tiotropium bromide(136310-93-5) significantly delays the onset of the first acute exacerbation in COPD patients, reduces the number of acute exacerbations per year, and reduces the risk of hospitalization and death during treatment in patients with acute exacerbations. SGRQ showed that tiotropium significantly improved the health-related quality of Life of patients. Notably, tiotropium significantly reduced the incidence of respiratory and cardiac complications, and has good safety. The study also suggested that tiotropium could achieve more significant clinical benefit in patients with moderate COPD (COPD Global Initiative (GOLD) II).

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved